RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, Co. is developing selective small molecules designed to modulate the immune responses underlying these diseases. Co.'s main inflammation drug candidate, RPT193, and its main oncology drug candidate, FLX475, each target C-C motif chemokine receptor 4, a drug target that potentially has applicability in inflammatory diseases and oncology. The RAPT stock yearly return is shown above.
The yearly return on the RAPT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RAPT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|